Logo image of ECAT

BLACKROCK ESG CAP ALL TRM TR (ECAT) Stock Overview

USA - NYSE:ECAT - US09262F1003

15.98 USD
-0.18 (-1.11%)
Last: 10/17/2025, 8:07:37 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ECAT. ECAT was compared to 0 industry peers in the Unkown industry. ECAT has a bad profitability rating. Also its financial health evaluation is rather negative. ECAT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ECAT had positive earnings in the past year.
In the past year ECAT had a positive cash flow from operations.
ECAT Yearly Net Income VS EBIT VS OCF VS FCFECAT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 -500M -1B -1.5B -2B

1.2 Ratios

The 3 year average ROIC (1.31%) for ECAT is below the current ROIC(1.35%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 8.5%
ROE 9.29%
ROIC 1.35%
ROA(3y)4.06%
ROA(5y)N/A
ROE(3y)3.82%
ROE(5y)N/A
ROIC(3y)1.31%
ROIC(5y)N/A
ECAT Yearly ROA, ROE, ROICECAT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 10 -10

1.3 Margins

ECAT's Profit Margin has declined in the last couple of years.
Industry RankSector Rank
OM 52.96%
PM (TTM) 285.19%
GM 59.26%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-48.47%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ECAT Yearly Profit, Operating, Gross MarginsECAT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 1K 2K

More info and screens

3

2. Health

2.1 Basic Checks

ECAT has less shares outstanding than it did 1 year ago.
Compared to 1 year ago, ECAT has an improved debt to assets ratio.
ECAT Yearly Shares OutstandingECAT Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 20M 40M 60M 80M 100M
ECAT Yearly Total Debt VS Total AssetsECAT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

ECAT has an Altman-Z score of 6.22. This indicates that ECAT is financially healthy and has little risk of bankruptcy at the moment.
ECAT has a debt to FCF ratio of 0.01. This is a very positive value and a sign of high solvency as it would only need 0.01 years to pay back of all of its debts.
A Debt/Equity ratio of 0.00 indicates that ECAT is not too dependend on debt financing.
Even though the debt/equity ratio score it not favorable for ECAT, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.01
Altman-Z 6.22
ROIC/WACCN/A
WACCN/A
ECAT Yearly LT Debt VS Equity VS FCFECAT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 1B -1B 2B -2B

2.3 Liquidity

ECAT has a Current Ratio of 0.05. This is a bad value and indicates that ECAT is not financially healthy enough and could expect problems in meeting its short term obligations.
A Quick Ratio of 0.05 indicates that ECAT may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 0.05
Quick Ratio 0.05
ECAT Yearly Current Assets VS Current LiabilitesECAT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

ECAT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -40.23%.
Measured over the past years, ECAT shows a very strong growth in Earnings Per Share. The EPS has been growing by 45.23% on average per year.
ECAT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -13.09%.
The Revenue has been growing by 175.73% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-40.23%
EPS 3Y45.23%
EPS 5YN/A
EPS Q2Q%-47.46%
Revenue 1Y (TTM)-13.09%
Revenue growth 3Y175.73%
Revenue growth 5YN/A
Sales Q2Q%-23.53%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ECAT Yearly Revenue VS EstimatesECAT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 20M 40M 60M

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 10.24, which indicates a very decent valuation of ECAT.
ECAT is valuated cheaply when we compare the Price/Earnings ratio to 27.40, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 10.24
Fwd PE N/A
ECAT Price Earnings VS Forward Price EarningsECAT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF 3.9
EV/EBITDA N/A
ECAT Per share dataECAT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

4

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 20.22%, ECAT is a good candidate for dividend investing.
ECAT's Dividend Yield is rather good when compared to the S&P500 average which is at 2.38.
Industry RankSector Rank
Dividend Yield 20.22%

5.2 History

ECAT has been paying a dividend for over 5 years, so it has already some track record.
ECAT has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years3
Div Non Decr Years3
ECAT Yearly Dividends per shareECAT Yearly Dividends per shareYearly Dividends per share 2021 2022 2023 2024 2025 0.5 1 1.5 2 2.5

5.3 Sustainability

235.71% of the earnings are spent on dividend by ECAT. This is not a sustainable payout ratio.
DP235.71%
EPS Next 2YN/A
EPS Next 3YN/A
ECAT Yearly Income VS Free CF VS DividendECAT Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2021 2022 2023 2024 0 -500M -1B -1.5B -2B
ECAT Dividend Payout.ECAT Dividend Payout, showing the Payout Ratio.ECAT Dividend Payout.PayoutRetained Earnings

More info and screens

BLACKROCK ESG CAP ALL TRM TR

NYSE:ECAT (10/17/2025, 8:07:37 PM)

15.98

-0.18 (-1.11%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)09-04 2025-09-04
Earnings (Next)03-02 2026-03-02
Inst Owners43.59%
Inst Owner Change-0.02%
Ins Owners0.11%
Ins Owner Change0%
Market Cap1.59B
Analysts0
Price TargetN/A
Short Float %0.42%
Short Ratio1.09
Dividend
Industry RankSector Rank
Dividend Yield 20.22%
Yearly Dividend2.87
Dividend Growth(5Y)N/A
DP235.71%
Div Incr Years3
Div Non Decr Years3
Ex-Date09-15 2025-09-15 (0.28757)
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 10.24
Fwd PE N/A
P/S 29.4
P/FCF 3.9
P/OCF 3.9
P/B 0.96
P/tB 0.96
EV/EBITDA N/A
EPS(TTM)1.56
EY9.76%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)4.1
FCFY25.64%
OCF(TTM)4.1
OCFY25.64%
SpS0.54
BVpS16.67
TBVpS16.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 8.5%
ROE 9.29%
ROCE 1.71%
ROIC 1.35%
ROICexc 1.35%
ROICexgc 1.35%
OM 52.96%
PM (TTM) 285.19%
GM 59.26%
FCFM 753.7%
ROA(3y)4.06%
ROA(5y)N/A
ROE(3y)3.82%
ROE(5y)N/A
ROIC(3y)1.31%
ROIC(5y)N/A
ROICexc(3y)1.31%
ROICexc(5y)N/A
ROICexgc(3y)1.34%
ROICexgc(5y)N/A
ROCE(3y)1.67%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-48.47%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.01
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion N/A
Profit Quality 264.29%
Current Ratio 0.05
Quick Ratio 0.05
Altman-Z 6.22
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-40.23%
EPS 3Y45.23%
EPS 5YN/A
EPS Q2Q%-47.46%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-13.09%
Revenue growth 3Y175.73%
Revenue growth 5YN/A
Sales Q2Q%-23.53%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-21.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y128.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y128.78%
OCF growth 3YN/A
OCF growth 5YN/A